| 產(chǎn)品編號 | bs-1120R-BF647 |
| 英文名稱1 | Rabbit Anti-FLIP/BF647 Conjugated antibody |
| 中文名稱 | BF647標記的凋亡調(diào)節(jié)基因之一抗體 |
| 別 名 | CASP8 and FADD-like apoptosis regulator subunit p12; c FLIP; c FLIPL; c FLIPR; c FLIPS; CASH; CASP8 and FADD like regulator; CASP8 and FADD like apoptosis regulator precursor; CASP8AP1; Caspase Eight Related Protein; Caspase homolog; Caspase Homologue; Caspase Like Apoptosis Regulatory Protein; Caspase related inducer of apoptosis; CASPER; Cellular FLICE like inhibitory protein; CFLA; CFLAR; CLARP; FADD like anti apoptotic molecule; FADD Like Anti-apoptotic Molecule 1; FADD like antiapoptotic molecule 1; FADD Like Apoptosis Regulator; FLAME 1; FLAME; FLAME1; FLICE Inhibitor Protein; FLIP; FLIPs; I FLICE; Inhibitor of FLICE; MACH Related Inducer of Toxicity; mFLIP; MRIT; USURPIN; Usurpin beta; FLICE-like inhibitory protein long form. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 細胞生物 信號轉(zhuǎn)導(dǎo) 細胞凋亡 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rat, (predicted: Chicken, Dog, Pig, Cow, Horse, Rabbit, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 12/52kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CASP8 and FADD-like apoptosis regulator subunit p12 (Potential) |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The protein encoded by this gene is a regulator of apoptosis and is structurally similar to caspase-8. However, the encoded protein lacks caspase activity and appears to be itself cleaved into two peptides by caspase-8. Several transcript variants encoding different isoforms have been found for this gene, and partial evidence for several more variants exists. [provided by RefSeq, Feb 2011]. Function: Apoptosis regulator protein which may function as a crucial link between cell survival and cell death pathways in mammalian cells. Acts as an inhibitor of TNFRSF6 mediated apoptosis. A proteolytic fragment (p43) is likely retained in the death-inducing signaling complex (DISC) thereby blocking further recruitment and processing of caspase-8 at the complex. Full length and shorter isoforms have been shown either to induce apoptosis or to reduce TNFRSF-triggered apoptosis. Lacks enzymatic (caspase) activity. Tissue Specificity: Widely expressed. Higher expression in skeletal muscle, pancreas, heart, kidney, placenta, and peripheral blood leukocytes. Also detected in diverse cell lines. Isoform 8 is predominantly expressed in testis and skeletal muscle. Post-translational modifications: Proteolytically processed; probably by caspase-8. Processing likely occurs at the DISC and generates subunit p43 and p12. Similarity: Belongs to the peptidase C14A family. Contains 2 DED (death effector) domains. Database links: Entrez Gene: 8837 Human Entrez Gene: 12633 Mouse Omim: 603599 Human SwissProt: O15519 Human SwissProt: O35732 Mouse Unigene: 390736 Human Unigene: 336848 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. FLIP參與凋亡的調(diào)節(jié)。此抗體在長型和短型的FLIP異構(gòu)體中均表達。短型FLIP包含2個死亡效應(yīng)基因結(jié)構(gòu)區(qū)，同源于FAS相關(guān)蛋白死亡效應(yīng)基因結(jié)構(gòu)區(qū)。長型FLIP包含1個附加的Caspase 樣結(jié)構(gòu)區(qū)，但是他缺少一個催化部位和在大多數(shù)Caspase 蛋白中形成底物結(jié)合束的殘基。 |
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
